NEW DELHI: Pfizer Inc launched the company’s first-ever dedicated commercial analytics centre in India, which is also the company’s first global capability centre for international markets.
The ‘Analytics Gateway‘ located in Mumbai is positioned to be a global capability centre (GCC) serving all of Pfizer’s international (ex-US) markets to bring analytics, and insight breakthroughs that will benefit patients, says a company statement.
The centre represents a significant milestone in Pfizer’s international commercial strategy and will play a pivotal role in driving the company’s growth across 140 international markets, utilizing cutting-edge data analytics, AI, and insights, it adds.
This comes even as several MNCs and pharma companies are shifting their India strategy from marketing and distribution, to setting up GCCs to support their international operations. India, dubbed as the GCC capital of the world, is reportedly expected to cross over $100 billion in GCC export revenue by 2029-30 financial year, up from $64.6 billion in 2023-24.
The centre that is set up in Mumbai, is expected to accelerate data science and AI solutions to meet Pfizer’s ambitions in modernizing marketing and creating an agile sales force. It will also drive continuous commercial effectiveness, enabling Pfizer to bring more of its medicines to more patients in India and around the world.
Meenakshi Nevatia, country president, Pfizer India, said, “The actionable insights generated by the Analytics Gateway will power up our global commercial engine as we modernize healthcare to meet the evolving needs of patients in India and worldwide and deliver strong patient outcomes.”
The ‘Analytics Gateway‘ located in Mumbai is positioned to be a global capability centre (GCC) serving all of Pfizer’s international (ex-US) markets to bring analytics, and insight breakthroughs that will benefit patients, says a company statement.
The centre represents a significant milestone in Pfizer’s international commercial strategy and will play a pivotal role in driving the company’s growth across 140 international markets, utilizing cutting-edge data analytics, AI, and insights, it adds.
This comes even as several MNCs and pharma companies are shifting their India strategy from marketing and distribution, to setting up GCCs to support their international operations. India, dubbed as the GCC capital of the world, is reportedly expected to cross over $100 billion in GCC export revenue by 2029-30 financial year, up from $64.6 billion in 2023-24.
The centre that is set up in Mumbai, is expected to accelerate data science and AI solutions to meet Pfizer’s ambitions in modernizing marketing and creating an agile sales force. It will also drive continuous commercial effectiveness, enabling Pfizer to bring more of its medicines to more patients in India and around the world.
Meenakshi Nevatia, country president, Pfizer India, said, “The actionable insights generated by the Analytics Gateway will power up our global commercial engine as we modernize healthcare to meet the evolving needs of patients in India and worldwide and deliver strong patient outcomes.”
